Dicot to Participate in Upcoming August Investor Conferences

Press release: Uppsala, August 21, 2019. Dicot AB (publ), developer of drugs targeting sexual dysfunction, today announced that Göran Beijer, CEO, will participate and host one-on-one investor meetings at the following upcoming investor conferences: BioStock Live Capital Markets Day and the LSX Nordic Congress 2019.

Event Details:

BioStock Live Capital Markets Day

Tuesday, August 27, 2019

Presentation at 10:00 AM CET

A live webcast of the presentation can be accesed via the following link: https://www.eventbrite.com/e/biostock-live-sthlm-august-27-biljetter-68783139221

LSX Nordic Congress 2019

Thursday, August 29, 2019

Hosting Investor Meetings

Göran Beijer will be representing the company and hosting one-on-one meetings during the conference. To schedule a meeting please contact the LSX Nordic Congress organizers or Gabriela Urquilla at [email protected].

For more information, please contact:

Julie Silber

CFO/Investor Relations Director, Dicot

Tel.: +46-79-3486277

Email: [email protected]

About Dicot AB (publ)

Dicot"s business concept is to develop the product LibiguinTM as a drug for the treatment of sexual dysfunctions. The development takes place in-house up to clinical phases. It is the company"s intention to subsequently enter into strategic alliances at appropriate times, or alternatively conduct a trade sale, with established major pharmaceutical companies to be able to introduce LibiguinTM on the world market. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. www.dicot.se

Attached files


Om Dicot Pharma

Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.



Kurs ()
Förändring ()
Marknad Spotlight Stock Market Kortnamn DICOT ISIN-kod SE0011178458


Elin Trampe Vd